Premium
Venetoclax as a single agent and in combination with PI3K‐MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma
Author(s) -
Jiang Huijuan,
Lwin Tint,
Zhao Xiaohong,
Ren Yuan,
Li Grace,
Moscinski Lynn,
Shah Bijal,
Tao Jianguo
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15079
Subject(s) - ibrutinib , kinome , pi3k/akt/mtor pathway , cancer research , mantle cell lymphoma , protein kinase b , biology , xiap , apoptosis , microbiology and biotechnology , kinase , chemistry , programmed cell death , signal transduction , immunology , lymphoma , biochemistry , leukemia , caspase , chronic lymphocytic leukemia